J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus